PMID- 20926123
OWN - NLM
STAT- MEDLINE
DCOM- 20101223
LR  - 20221207
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 120
IP  - 1
DP  - 2011 Jan
TI  - The value of p16ink4a expression by fluorescence in situ hybridization in triage 
      for high risk HPV positive in cervical cancer screening.
PG  - 84-8
LID - 10.1016/j.ygyno.2010.09.008 [doi]
AB  - OBJECTIVES: The aim of this study is to evaluate the effect of fluorescence in 
      situ hybridization (FISH) detection for p16ink4a expression as an alternative 
      triage for high risk HPV positive women in cervical cancer screening. METHODS: 
      Totally 191 cervical cell specimens from women with HPV positive were collected. 
      The p16ink4a expression by FISH and liquid-based thin-layer cytology was 
      performed and followed by colposcopy with or without biopsied histologic 
      examination for all participants. The relationship between p16ink4a expression 
      and histologic diagnosis, as well as cytology was analyzed. RESULTS: The positive 
      rate of p16ink4a was 5.35% in normal or inflammation cases, 56.67% in CIN 1, 
      83.78% in CIN 2-3, 100.00% in carcinoma, respectively, with a significance 
      between <CIN2 and >/=CIN 2 (P<0.001). The p16ink4a expression presented a 
      concordance trend as cytology grading, with a positive rate of 9.28% in NILM, 
      33.33% in ASCUS, 53.37% in LSIL, 81.25% in ASC-H, and 95% in HSIL, respectively. 
      Compared with cytology, FISH detection for p16ink4a had a higher accuracy (84.8% 
      vs. 74.34%), higher sensitivity (87.75% vs. 52.00%) and similar specificity 
      (83.84% vs. 88.79%) for predicting >/=CIN 2 lesions. CONCLUSIONS: FISH detection 
      specific to p16ink4a presents a high consistency with cytologic grading and has a 
      higher accuracy for predicting high grade CIN than cytology in high risk HPV 
      positive women. Our findings suggest that FISH detection for p16ink4a is a 
      potential alternative triage for high-risk HPV positive women in cervical cancer 
      screening.
CI  - Copyright (c) 2010 Elsevier Inc. All rights reserved.
FAU - Zeng, Wen-Jie
AU  - Zeng WJ
AD  - Women's Reproductive Health Laboratory of Zhejiang Province, China.
FAU - Li, Ying
AU  - Li Y
FAU - Fei, Hua-Li
AU  - Fei HL
FAU - Cheng, Xiao-Dong
AU  - Cheng XD
FAU - Ye, Feng
AU  - Ye F
FAU - Lu, Wei-Guo
AU  - Lu WG
FAU - Xie, Xing
AU  - Xie X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101008
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Adult
MH  - Cyclin-Dependent Kinase Inhibitor p16/analysis/*biosynthesis/genetics
MH  - DNA, Viral/analysis/genetics
MH  - Early Detection of Cancer/methods
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Papillomaviridae/genetics/isolation & purification
MH  - Papillomavirus Infections/genetics/*metabolism/pathology
MH  - Risk Factors
MH  - Uterine Cervical Neoplasms/genetics/*metabolism/*virology
MH  - Young Adult
MH  - Uterine Cervical Dysplasia/genetics/metabolism/virology
EDAT- 2010/10/12 06:00
MHDA- 2010/12/25 06:00
CRDT- 2010/10/08 06:00
PHST- 2010/07/14 00:00 [received]
PHST- 2010/09/01 00:00 [revised]
PHST- 2010/09/03 00:00 [accepted]
PHST- 2010/10/08 06:00 [entrez]
PHST- 2010/10/12 06:00 [pubmed]
PHST- 2010/12/25 06:00 [medline]
AID - S0090-8258(10)00688-8 [pii]
AID - 10.1016/j.ygyno.2010.09.008 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2011 Jan;120(1):84-8. doi: 10.1016/j.ygyno.2010.09.008. Epub 2010 
      Oct 8.